Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Stéphanie Malartre"'
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background The French healthcare system is characterised by a shift towards outpatient care and the desire to develop telemedicine affirmed in the collective commitment “Ma santé 2022” presented by President Macron in 2018. In France, r
Externí odkaz:
https://doaj.org/article/3bfa07e64595496096c99609807afba3
Publikováno v:
La Revue de l'Infirmière. 71:24-26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a3aff8883ed45ed88ac2477aa9cbcae
https://doi.org/10.1016/j.revinf.2022.03.009
https://doi.org/10.1016/j.revinf.2022.03.009
Publikováno v:
Revue de l'infirmiere. 71(281)
In France, the number of cancer survivors is expected to increase significantly in the coming years. However, there seems to be a lack of identification and management of complications after treatment. Coordination nurses and advanced practice nurses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c4be1d5ee18baf20c3a544a048ab8f5b
https://pubmed.ncbi.nlm.nih.gov/35843637
https://pubmed.ncbi.nlm.nih.gov/35843637
Autor:
Stéphanie Malartre, Cristina Bagacean, Véronique Leblond, Aline Clavert, Hugo Legendre, Caroline Dartigeas, Nanthara Sritharan, Bernard Drenou, Kamel Laribi, Xavier Troussard, Ségolène Brichler, Anne-Sophie Michallet, Driss Chaoui, Alain Delmer, Lise Willems, Christian Puppinck, Cécile Tomowiak, Fatiha Merabet, Damien Roos-Weil, Chadi Al-Nawakil, Florence Cymbalista, Rémi Letestu, Marie C. Béné, Romain Guieze, Vincent Levy, Philippe Genet
Publikováno v:
Blood Advances
Blood Advances, The American Society of Hematology, 2022, 6 (1), pp.207-211. ⟨10.1182/bloodadvances.2021006215⟩
Blood Advances, The American Society of Hematology, 2022, 6 (1), pp.207-211. ⟨10.1182/bloodadvances.2021006215⟩
Immunocompromised individuals such as patients with chronic lymphocytic leukemia (CLL) are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8f6ff29fe1b1f71f722a373e71a0ebd
http://europepmc.org/articles/PMC8632355
http://europepmc.org/articles/PMC8632355
Autor:
Damien Roos-Weil, Alain Delmer, Lise Willems, Xavier Troussard, Nanthara Sritharan, Aline Clavert, Anne-Sophie Michallet, Philippe Genet, Hugo Legendre, Cristina Bagacean, Véronique Leblond, Caroline Dartigeas, Kamel Laribi, Bernard Drenou, Fatiha Merabet, Christian Puppink, Vincent Levy, Yamina Touileb, Cécile Tomowiak, Stéphanie Malartre, Rémi Letestu, Driss Chaoui, Florence Cymbalista, Chadi Al Nawakil, Romain Guieze, Marie C. Béné, Ségolène Brichler
Publikováno v:
Blood
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an ongoing global pandemic. Phase III trials have demonstrated excellent efficacies of mRNA vaccines against SARS-CoV-2 in large population studies (Baden LR, NEJM, 2021;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee938e3ae2920f3a86bdffd36d78210
http://europepmc.org/articles/PMC8701581
http://europepmc.org/articles/PMC8701581